Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22372221 | 0.81 | NPC1 (0.44) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2426685 | 0.79 | NPC1 (0.45) | NPC1RAB9AKMT2AALDH1A1TAAR1 | |
| SCHEMBL22372217 | 0.78 | NPC1 (0.41) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1887631 | 0.77 | NPC1 (0.41) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5161632 | 0.76 | NPC1 (0.42) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL22372037 | 0.76 | NPC1 (0.40) | NPC1RAB9AKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL11803527 | 0.76 | POLB (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL7048212 | 0.76 | RAB9A (0.58) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10941407 | 0.76 | — | — | |
| SCHEMBL98748 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4562002-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Nodus Oncology Limited (GB) | 2025-06-04 | — | — | EP | disclosed |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-01 | — | — | US | disclosed |
| WO-2024023330-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | NODUS ONCOLOGY LIMITED (GB) | 2024-02-01 | — | — | WO | disclosed |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-23 | — | — | US | disclosed |
| CN-107001375-B | 6, 7-dihydropyrazolo [1,5-a ] pyrazin-4 (5H) -one compounds and their use as negative allosteric modulators of MGLUR2 receptors | 詹森药业有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-10472352-B2 | Rac inhibitors | Geneyus LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190031647-A1 | RAC INHIBITORS | Geneyus LLC (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2017093545-A1 | ANTI-BACTERIAL COMPOUNDS BASED ON AMINO-GOLD PHOSPHINE COMPLEXES | AUSPHERIX LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-0541705-A4 | SUBSTITUTED 1H-IMIDAZOL-5-YL)ALKANOIC ACIDS | — | 1993-11-10 | — | — | EP | disclosed |
| EP-0541705-A1 | SUBSTITUTED 1H-IMIDAZOL-5-YL]ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | PTGS1, PTGER1, TBXA2R | NPC1 3524/4885RAB9A 2660/4885KMT2A 3245/4885 |
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ROS1, MCL1, ALK | NPC1 468/4885RAB9A 1675/4885KMT2A 1919/4885 |
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | NPC1 4323/4885RAB9A 2864/4885KMT2A 3446/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | NPC1 372/4885RAB9A 1870/4885KMT2A 3191/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | NPC1 2133/4885RAB9A 2200/4885KMT2A 1719/4885 |
| US-20190031647-A1 | RAC INHIBITORS | ARHGDIB, ARHGDIA, RAC1 | NPC1 1118/4885RAB9A 44/4885KMT2A 2995/4885 |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | CYP51A1, MPO, NOX5 | NPC1 2556/4885RAB9A 3264/4885KMT2A 4305/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | NPC1 50/4885RAB9A 377/4885KMT2A 2133/4885 |
| US-10472352-B2 | Rac inhibitors | ARHGDIB, ARHGDIA, RAC1 | NPC1 1118/4885RAB9A 44/4885KMT2A 2995/4885 |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | CYP51A1, MPO, NOX5 | NPC1 2556/4885RAB9A 3264/4885KMT2A 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.